Study of Surgical Techniques During Cystectomy for Bladder Cancer
This study is looking at two common surgical techniques used during a radical cystectomy (surgery to remove the bladder) for bladder cancer. Researchers want to see if using a ureteral stent (a thin tube to help urine drain) or the medication alvimopan (to help bowel function return after surgery) changes how long you stay in the hospital or your risk of infection after surgery. You may be able to join if you are at least 21 years old and are having a radical cystectomy for bladder cancer with one of the participating surgeons. The study will consider how long you stay in the hospital and if you get a urinary tract infection within 30 days of surgery. The current status of this study is unclear, and it plans to enroll 530 people.
- Study design
- This is an interventional study, meaning participants will receive specific treatments. It plans to enroll 530 participants.
- What's involved
- If you receive alvimopan, you will take a dose before surgery and then twice daily after surgery for up to 7 days or until you leave the hospital. If you receive a stent, it will be placed during surgery.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will measure your length of hospital stay (for alvimopan) and check for symptomatic urinary tract infections within 30 days of surgery (for stents).
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study of Surgical Techniques During Cystectomy
At a glance
Conditions
NCT06703476
Where you'd take part
This study runs at 7 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Memorial Sloan Kettering at Basking Ridge (Consent Only)
Basking Ridge, New Jerseystudy coordinator listed
Recruiting
Memorial Sloan Kettering Bergen (Consent Only)
Montvale, New Jerseystudy coordinator listed
Recruiting
Memorial Sloan Kettering Cancer Center (All Protocol Activites)
New York, New Yorkstudy coordinator listed
Recruiting
Memorial Sloan Kettering Monmouth (Consent Only)
Middletown, New Jerseystudy coordinator listed
Recruiting
Memorial Sloan Kettering Nassau (Consent Only)
Rockville Centre, New Yorkstudy coordinator listed
Recruiting
Memorial Sloan Kettering Suffolk-Commack (Consent Only)
Commack, New Yorkstudy coordinator listed
Recruiting
Memorial Sloan Kettering Westchester (Consent Only)
Harrison, New Yorkstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Alvin Goh, MD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Length of hospital stay (Alvimopan)greater than 6 days
it will define success for the intervention as a length of stay \<6 days (6 days is the current median length of stay).
- Symptomatic urinary tract infections (Stents)within 30 days of surgery
defined as the presence of signs or symptoms indicative of infection (fever, flank or abdominal pain, leukocytosis, radiographic imaging consistent with pyelonephritis) and a positive urine culture (\>100,000 CFU pathogenic bacteria on an appropriately collected urine specimen).